J&J settles Risperdal cases, avoiding former FDA commish's testimony

Johnson & Johnson has again backed down on its defense of Risperdal cases alleging that it caused boys who were given the antipsychotic to grow breasts.

Johnson & Johnson ($JNJ) on Thursday settled 5 pending cases for undisclosed sums, the Philadelphia Inquirer reports, dodging the chance that former FDA Commissioner David Kessler would be allowed to testify against the company. He was prepared to say J&J broke the law by promoting the drug for use in children.

"A drug company has a responsibility, independent of what FDA directs it to do, to alert physicians and patients to the risks that were unknown to or poorly understood by the FDA, but were known to the company," Kessler said in a report submitted to the court.

The company last month settled a similar case in which the plaintiff's lawyers were pressing hard to make J&J CEO Alex Gorsky testify as to why the company was pushing doctors to prescribe the drug to adolescents even though it was not approved at the time for that use.

A spokeswoman told the Inquirer that the policy of J&J's Janssen subsidiary at the time was not to promote the drug except for FDA approved uses. But that defense has not stood up too well in some cases. A jury in Arkansas awarded a $1.2 billion verdict there in a case alleging mismarketing, a sum that J&J is appealing as excessive.

The company in August reached a settlement with 36 states and the District of Columbia over the marketing of the drug that tops $180 million. It said in a public filing in July that it has reached a deal in principle with federal authorities. It has been reported that that settlement could reach $2.2 billion. There are about 400 individual cases pending.

- read the Philadelphia Inquirer story
- get more from Bloomberg

Related Articles:
J&J aims to block ex-FDA chief's testimony in Risperdal case
J&J to pay states $181M to resolve Risperdal cases
Witness: J&J aimed Risperdal pitch at childrens' doctors
Judge lets Gorsky off the hook in Risperdal case

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.